NCT02307838 - Long-term Follow-up of Fingolimod Phase II Study Patients | Biotech Hunter

Enrollment

177

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Interventions

OTHER

Assessments arm

Protocol required assessments not provided in standard of care

Trial Locations (26)

4031

Novartis Investigative Site, Basel

8091

Novartis Investigative Site, Zurich

13385

Novartis Investigative Site, Marseille

16132

Novartis Investigative Site, Genova

20132

Novartis Investigative Site, Milan

21013

Novartis Investigative Site, Gallarate

28040

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

41009

Novartis Investigative Site, Seville

46026

Novartis Investigative Site, Valencia

59037

Novartis Investigative Site, Lille

97080

Novartis Investigative Site, Würzburg

K1H 8L6

Novartis Investigative Site, Ottawa

M5B 1N9

Novartis Investigative Site, Toronto

H2L 4M1

Novartis Investigative Site, Montreal

H3A 2B4

Novartis Investigative Site, Montreal

DK-2100

Novartis Investigative Site, Copenhagen

DK-2600

Novartis Investigative Site, Glostrup Municipality

00189

Novartis Investigative Site, Roma

02-097

Novartis Investigative Site, Warsaw

02-957

Novartis Investigative Site, Warsaw

3000-075

Novartis Investigative Site, Coimbra

1150-314

Novartis Investigative Site, Lisbon

08035

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne